Community Theatre

Debate between Chris Bryant and Alison Bennett

Wednesday 12th March 2025 Westminster Hall

[Chris Bryant]

I like the way that the hon. Lady casually dismisses the £85 million of capital investment—it took quite a lot of work to secure that money. One of the first things that the Secretary of State for Culture, Media and Sport and I were lobbied about when we came into government last July was the state of many of the cultural institutions—theatres, museums, galleries and so on—that have been run by local authorities and are in dire capital need. Many of the organisations that we are talking about will be covered by that. If she wants to write to me about the specifics of that case, I will look into it. We had to decide where our priorities should lie. There are other avenues that other organisations can go down, but we wanted to make sure that there was a solid amount of money available in a single year: £85 million for capital projects in 2025-26 for the kind of theatres that many of us will be talking about that are, or have been, local authority-run.

The other intervention that the Department is engaged in is the Theatres Trust, which provides a great deal of unbiased advice to a variety of different theatres about their funding mechanism, their legal structures, their governance and what they can do about energy costs—a whole series of different things. I am very grateful to the Theatres Trust team, who play an important role in making sure that the whole sector works.

It is clearly easy for us to celebrate the big shows that I have already mentioned in the west end, such as Tom Hiddleston in “Much Ado About Nothing”. Those productions get lots of coverage and are very successful commercially, but we cannot have a successful commercial UK theatre industry without a successful subsidised UK theatre industry. We need that whole mix. An actress such as Glenda Jackson, who ended up winning two Oscars and was nominated for two more, and who was a great star of stage and screen making her way partly in theatre and partly in the movies, started in rep in Hoylake and West Kirby. We must remember that it is that whole mix, even in the changing environment of modern theatre, which has very few repertory theatres in the classic sense, that we really have to sustain.

I have already referred to the £85 million creative foundations fund, but I should also refer, as the hon. Member for Hazel Grove rightly did, to local government. The new plan for neighbourhoods that is being developed by the Ministry of Housing, Communities and Local Government is precisely designed to look at how we can make sure our local neighbourhoods flourish. A key aspect of that must be the creative industries and our cultural institutions. People take so much pride in having a local theatre, a local music venue or whatever else it may be. We lose those organisations at our peril, although there are enormous challenges.

[Alison Bennett]

My concern is that, in west Sussex, we are on the fast track for local government reorganisation, and without a quick resolution to how we fund social care, many of the community theatres, which are council-owned assets, are at risk of being sold off. Would the Minister press the Ministry of Housing, Communities and Local Government on that point?

[Chris Bryant]

I have already had those conversations with the Ministry; it is obviously not simple when we are talking about local government reorganisation. I used to be a councillor in Hackney, so I know the pressures that are always on local government, but those pressures have been so intense for the last 14 years, with an ageing population taking up a much greater proportion of funding through social care, and looking after children in care, as well as very diminished budgets. Local authorities have really struggled to do what they are required to do, let alone what they are allowed to do, such as providing culture and leisure facilities.

One of the problems has been that local authorities have tended to have annual settlements rather than three-year settlements, and I hope that more of the latter will make a dramatic difference to how local authorities can plan for big and medium-sized projects in the cultural sphere. However, I will always make the case to any local councillor who walks through the door that simply cutting funding for the local theatre or leisure centre is an own goal. I tell them that they would then struggle to provide other services, lose pride in their local place, deprive people of career opportunities and make it more difficult to grow the local economy. We know that for every £1 spent on a theatre ticket or a live performance ticket, people are likely to spend several more on other things in the local community.

AstraZeneca

Debate between Chris Bryant and Alison Bennett

Monday 3rd February 2025 Commons Chamber

[Chris Bryant]

I would be delighted to meet my hon. Friend knows, as she knows, although I think it would probably be more useful for her if she were to meet Lord Vallance, who is the Minister for life sciences. My hon. Friend is absolutely right; we would of course much prefer this investment to go ahead and to have been able to get this deal over the line. However, it has not been possible, and we now have to look at different ways of ensuring that we strengthen the relationship with AstraZeneca. However, I would point to other investments that have been made in recent months, including in life sciences, to quite significant effect.

[Alison Bennett (Mid Sussex) (LD)]

The Financial Times reports that, during its negotiations with the Government, AstraZeneca raised concerns about the vaccine plant, but also about the rejection of one of its breast cancer drugs and the drug pricing mechanism. Does the Minister agree that AstraZeneca’s rejection of his Government’s final offer is not the only concerning issue for our biopharma industry, and will he assure me that he is raising issues around the regulatory and reimbursement processes with the Health Secretary and the Treasury as barriers to growth in a sector already struggling with post-Brexit red tape?

[Chris Bryant]

The hon. Lady’s first point was on the voluntary scheme for branded medicines pricing and access, which is reduced to an acronym that is not really an acronym: VPAG. This is, as it says on the tin, a voluntary agreement between Government, the pharmaceutical industry and the NHS, which is designed specifically to ensure that we protect the NHS’s medicines budget. It is voluntary, and AstraZeneca has always been a party to it on a voluntary basis. I am not sure that is the problem the hon. Lady thinks it is—although, if she has further evidence, I would be happy to speak to her.

I think she is also referring to the rejection by the National Institute for Health and Care Excellence of a breast cancer drug. This is the first time in six years that a breast cancer drug has been rejected by NICE, and it is obviously concerning for everybody who wants to be able to use these drugs. However, we have an independent and much-respected system in the UK. I stand by that independence; I am not going to undermine it.